Evidence map›Paper›PMID 29766039›Full record

ArticleeNeuro

Beneficial Outcome of Urethane Treatment Following Status Epilepticus in a Rat Organophosphorus Toxicity Model.

Asheebo Rojas, Wenyi Wang, Avery Glover, Zahra Manji, Yujiao Fu, Raymond Dingledine

Open access · goldAbstract readComparative Study
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Anti-seizure effects of WS-3, a TRPM8 agonist, on focal onset seizure mouse model via reduction of extracellular glutamate levels.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  16. Article
  17. Review
  18. Differential Impact of Severity and Duration ofFrontiers in cellular neuroscience · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Asheebo RojasDepartment of Pharmacology, Emory University, Atlanta, GA 30322.
Wenyi WangDepartment of Pharmacology, Emory University, Atlanta, GA 30322.
Avery GloverDepartment of Pharmacology, Emory University, Atlanta, GA 30322.
Zahra ManjiDepartment of Pharmacology, Emory University, Atlanta, GA 30322.ORCID 0000-0003-2121-2881
Yujiao FuDepartment of Pharmacology, Emory University, Atlanta, GA 30322.
Raymond DingledineDepartment of Pharmacology, Emory University, Atlanta, GA 30322.
Emory University · US

Funding

ENNCF - Viral Vector CoreP30NS055077 · NINDS · EMORY UNIVERSITY · PI LEVEY, ALLAN I · 2008 to 2018
$6.8M
Prostanoid modulators that reduce brain injury and inflammation after seizuresU01NS058158 · NINDS · EMORY UNIVERSITY · PI DINGLEDINE, RAYMOND J · 2006 to 2015
$5.9M
Training Program in Neurobiology of Drug AbuseT32DA015040 · NIDA · EMORY UNIVERSITY · PI KUHAR, MICHAEL J · 2003 to 2012
$3.6M
Inflammatory control of blood-brain barrier integrity and epileptogenesis after seizuresR01NS097776 · NINDS · EMORY UNIVERSITY · PI DINGLEDINE, RAYMOND J · 2016 to 2020
$2.2M
NIDA NIH HHS T32 DA015040NINDS NIH HHS P30 NS055077NINDS NIH HHS R01 NS097776NINDS NIH HHS U01 NS058158
6 · The paper itself

Abstract

The efficacy of benzodiazepines to terminate electrographic status epilepticus (SE) declines the longer a patient is in SE. Therefore, alternative methods for ensuring complete block of SE and refractory SE are necessary. We compared the ability of diazepam and a subanesthetic dose of urethane to terminate prolonged SE and mitigate subsequent pathologies. Adult Sprague Dawley rats were injected with diisopropylfluorophosphate (DFP) to induce SE. Rats were administered diazepam (10 mg/kg, ip) or urethane (0.8 g/kg, s.c.) 1 h after DFP-induced SE and compared to rats that experienced uninterrupted SE. Large-amplitude and high-frequency spikes induced by DFP administration were quenched for at least 46 h in rats administered urethane 1 h after SE onset as demonstrated by cortical electroencephalography (EEG). By contrast, diazepam interrupted SE but seizures with high power in the 20- to 70-Hz band returned 6-10 h later. Urethane was more effective than diazepam at reducing hippocampal neurodegeneration, brain inflammation, gliosis and weight loss as measured on day 4 after SE. Furthermore, rats administered urethane displayed a 73% reduction in the incidence of spontaneous recurrent seizures after four to eight weeks and a 90% reduction in frequency of seizures in epileptic rats. By contrast, behavioral changes in the light/dark box, open field and a novel object recognition task were not improved by urethane. These findings indicate that in typical rodent SE models, it is the return of SE overnight, and not the initially intense 1-2 h of SE experience, that is largely responsible for neurodegeneration, accompanying inflammation, and the subsequent development of epilepsy.

Indexed as

Anesthetics, GeneralAnimalsAnticonvulsantsDiazepamDisease Models, AnimalElectrocorticographyEnzyme InhibitorsGliosisHippocampusInflammationIsoflurophateNeurodegenerative DiseasesRatsRats, Sprague-DawleyStatus EpilepticusUrethaneAnesthetics, GeneralAnticonvulsantsDiazepamEnzyme InhibitorsIsoflurophateUrethaneDFPdiazepamEEGhippocampusneurodegenerationurethane

Identifiers

PMID29766039
PMCPMC5952304
OpenAlexW2799820526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.